PatientsVille.com Logo

VISUAL IMPAIRMENT and Celexa

PatientsVille

VISUAL IMPAIRMENT Symptoms and Causes

If you have low vision, eyeglasses, contact lenses, medicine, or surgery may not help. Activities like reading, shopping, cooking, writing, and watching TV may be hard to do. The leading causes of low vision and blindness in the United States are age-related eye diseases: macular degeneration, cataract and glaucoma. Other eye disorders, eye injuries, and birth defects can also cause vision loss.

Whatever the cause, lost vision cannot be restored. It can, however, be managed. A loss of vision means that you may have to reorganize your life and learn new ways of doing things. If you have some vision, visual aids such as special glasses and large print books can make life easier. There are also devices to help those with no vision, like text-reading software and braille books.

The sooner vision loss or eye disease is found and treated, the greater your chances of keeping your remaining vision. You should have regular comprehensive eye exams by an eye care professional.

NIH: National Eye Institute

Check out the latest treatments for VISUAL IMPAIRMENT

VISUAL IMPAIRMENT treatment research studies

Celexa clinical trials, surveys and public health registries


Find Drug Side Effect reports



Celexa Side Effects

Dizziness (136)
Nausea (135)
Anxiety (127)
Suicidal Ideation (124)
Depression (123)
Headache (120)
Completed Suicide (120)
Pain (111)
Insomnia (109)
Feeling Abnormal (102)
Vomiting (101)
Diarrhoea (99)
Fall (96)
Fatigue (91)
Loss Of Consciousness (89)
Tremor (89)
Dyspnoea (85)
Agitation (78)
Confusional State (76)
Aggression (69)
Asthenia (38)
Convulsion (34)
Suicide Attempt (33)
Condition Aggravated (32)
Abnormal Behaviour (32)
Weight Increased (31)
Somnolence (30)
Anger (30)
Pulmonary Embolism (28)
Malaise (28)
Chest Pain (28)
Crying (27)
Irritability (27)
Abdominal Pain Upper (25)
Abdominal Pain (25)
Constipation (25)
Overdose (25)
Serotonin Syndrome (25)
Paraesthesia (25)
Syncope (24)
Amnesia (24)
Hyperhidrosis (24)
Intentional Self-injury (22)
Hypertension (21)
Arthralgia (21)
Injury (20)
Palpitations (20)
Heart Rate Increased (20)
Blood Pressure Increased (20)
Rash (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Can ratio-citalopram be taken long term with Lectopam 6 mg?

Celexa triggered my tourettes syndrome. Three weeks after starting this med, I started having motor and vocal tics. Do not advise anyone to take this drug. It sucks.

I need to find out if Celexa is available in Ecuador as I will be living there for several months. Thanks.

I Took celexa for about 7 years im a 28 year old male. A couple months after getting off of the drug I have been twitching all over my body. Feet, legs,thighs,arms,stomach,hands,face,everywhere. I also have this feeling of a lump stuck in my throat.

It probably didn't trigger your TS. It was probably just supressing symptoms to a point where they were un noticable. Celexa is something they use to help alleviate the symptoms. so when you came off of it, they came back. They could have developed w

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

49yo female, 2/7 days use. Dose 15mg daily, after food. Experiencing severe headaches, visual disterbances, intermittent confusion, visual dreams/ hallucinations, exhaustion.

After about one month on the monthly dosage of Actonel I experienced jaw pain, muscle and joint pain and visual disturbances. Doctor wants to put me on Boniva. I've already tried Fosomax which caused me to have difficulty swallowi

Does long times usage of Concor 5mg cause any function in my health like memory impairment ?

Ever since I was on Sensipar ive been getting Migraines.'Visual first then Migrain following

I am a 67 yr old female, was prescribed Istn in 1990, and had no problem until two years ago. I then started to experience quite severe side effects, headaches, dizziness, nausea, visual disturbances, fatigue, anxiety among others. Since then my doct

I experienced a severe visual impairment, white sparkling lights to point of sight loss, distorted audio , near loss of bodily functions, severe h/a, sweating, chest pains, taste of the medication? in my mouth, unable to respond or move. It was horri

I have been taking crestor for about four years for highly elevated hdl. First 20mg now 10mg and am increasingly concerned that increased lethergy, cognitive impairment - short term memory loss and aphasia as well as chronic muscle ache may be a resu

I have been taking Pariet for over 6 months &amp; just realised I must be suffering side effects...reoccuring Flu symptoms &amp; Rhinitis, occasional leg cramps &amp; awakening with visual disturbances.

I have been using Garasone drops and recently (10 days ago) I have been experiencing vertigo and visual disturbances. I stoped the drops and what should I do now.

VISUAL IMPAIRMENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting EScitalopram PIndolol ONset of Action
Condition: Unipolar Depression
Interventions: Drug: escitalopram, pindolol;   Drug: escitalopram
Outcome Measures: MADRS score change between baseline and 2 weeks of treatment;   Response/remission (MADRS) at 6 weeks;   Adverse events;   Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups
2 Recruiting Lexapro®'s Efficacy After Dose Escalation in Remission Study
Condition: Major Depressive Disorder
Intervention: Drug: escitalopram
Outcome Measures: Montgomery-Åsberg Depression Rating Scale (MADRS);   Hamilton Depression Rating Scale-17 items (HAM-D);   Hamilton Anxiety Rating Scale (HAM-A);   Clinical Global Impression-severity (CGI-S);   Clinical Global Impression-Improvement (CGI-I);   Beck's Depression Inventory(BDI);   WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF);   Clinically Useful Depression Outcome Scale (CUDOS);   Short From-36 Health survey (SF-36 Health survey)
3 Unknown  Circadian Effects of Escitalopram
Condition: Depression
Intervention: Drug: placebo/escitalopram
Outcome Measures: Resetting effect of Escitalopram on the circadian pacemaker;   Correlation between improvement in depression with Escitalopram and the degree of realignment between the timing of sleep and the timing of the biological clock.
4 Recruiting Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
Conditions: Major Depressive Disorder;   Major Depressive Disorder, Recurrent, Unspecified;   Major Depressive Disorder, Single Episode, Unspecified
Interventions: Drug: Escitalopram oxalate;   Device: transcranial direct current stimulation
Outcome Measures: Change in Hamilton Rating Scale for Depression, 17 items (HAMD17);   Change in Montgomery-Asberg Depression Rating Scale (MADRS);   Change in Beck Depression Inventory (BDI);   Hamilton Rating Scale for Depression, 17 items (HAMD17)
5 Recruiting Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder
Conditions: Irritable Bowel Syndrome;   Panic Disorder
Intervention: Drug: Escitalopram
Outcome Measures: Gastrointestinal Symptom Rating Scale (GSRS).;   State Trait Anxiety Inventory (STAI).
6 Unknown  Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
Conditions: Low Back Pain;   Depression
Interventions: Drug: Escitalopram;   Drug: Placebo
Outcome Measures: In comparison to placebo-treated patients, patients with treated with Cipralex report a significant reduction in depressive symptoms (>= 50% HAMD score) after 4 weeks of treatment.;   In comparison to placebo, subjects treated with Cipralex report a significant reduction in pain intensity (>= 50% reduction of pain questionnaire score or VAS) after 12 weeks of treatment.;   In comparison with placebo, subjects treated with Cipralex report a significant improvement in physical and everyday functioning after 12 weeks of treatment.;   Personality traits do not have a significant influence on outcome regarding depressive traits, pain intensity and functioning.;   Personality disorders are significantly influencing worse outcome regarding depressive traits, pain intensity and functioning.
7 Recruiting DECIFER: DEpression and Citalopram In First Episode Recovery
Conditions: Schizophrenia;   Schizophreniform Disorder
Interventions: Drug: Citalopram;   Behavioral: Psychoeducation;   Behavioral: Cognitive Behavioral Therapy (CBT);   Radiation: Functional Magnetic Resonance Imaging (fMRI);   Drug: Placebo
Outcome Measures: Calgary Depression Scale for Schizophrenia (CDSS);   Scale for the Assessment of Negative Symptoms (SANS);   Brief Psychiatric Rating Scale (BPRS);   InterSePT Scale for Suicidal Thinking (ISST);   Heinrich Quality of Life Scale (QOL)
8 Not yet recruiting Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Agomelatine;   Drug: Escitalopram
Outcome Measures: Change from baseline in markers of sympathetic nervous system activity.;   Change from baseline in the magnitude of morning surge in blood pressure.;   To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.;   Change from baseline in insulin resistance.;   Change from baseline on markers of cardiac risk.
9 Unknown  Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)
Condition: Major Depression
Interventions: Drug: escitalopram;   Drug: nortriptyline
Outcome Measures: Hamilton depression rating scale;   Drop out due to side-effects of drugs
10 Recruiting Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Condition: Alcohol Dependence
Intervention: Drug: citalopram
Outcome Measures: Craving for alcohol in type B alcohol dependence with citalopram compared to placebo;   Striatal dopamine receptor availability in type B alcohol dependence with citalopram, compared to placebo
11 Unknown  The Effects of Escitalopram on Cytokines
Condition: Depression
Intervention: Drug: Escitalopram
Outcome Measures: The changes in cytokines;   The changes in Hamilton Depression Rating Scale
12 Recruiting Brain Aging and Treatment Response in Geriatric Depression
Conditions: Mild Neurocognitive Disorder;   MCI;   Depression
Interventions: Drug: Escitalopram;   Drug: Memantine;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale (HDRS) scores;   Change in cognitive domain scores
13 Unknown  Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Conditions: Depression;   Continuous Antidepressant Abuse;   Adverse Reaction to Drug
Intervention: Drug: Escitalopram
Outcome Measures: antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks;   biological value at 0 week and 8 weeks
14 Not yet recruiting The ISLAND Study: InSuLa Assessed Needs for Depression
Condition: Depression
Interventions: Drug: Escitalopram;   Behavioral: Cognitive Behavioral Therapy;   Other: Combination treatment (Escitalopram + CBT)
Outcome Measures: Remission from major depressive episode;   Response to treatment
15 Unknown  Citalopram for Cocaine Dependence
Condition: Cocaine Dependence
Interventions: Drug: Citalopram;   Drug: Placebo
Outcome Measures: Abstinence;   Cocaine Use Days;   Cocaine-negative Urines;   Retention in Treatment
16 Recruiting A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
Condition: Depressive Disorder, Major
Intervention: Drug: Escitalopram
Outcome Measures: Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF);   Change From Baseline in Sheehan Disability Scale (SDS);   Remission Rate at Week 8;   Onset of Effect Rate at Week 1;   Onset of Effect Rate at Week 2;   Change From Baseline to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Scores;   Change From Baseline to Week 8 in Hamilton Anxiety Scale (HAMA) Scores;   Change From Baseline to Week 8 in Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) Scores
17 Unknown  Cipralex® for Anxiety Disorders in Adolescents
Condition: Anxiety Disorder
Intervention: Drug: Cipralex®
Outcome Measures: Treatment Efficacy;   Physiological response to stress;   Suicide risk
18 Recruiting Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults
Condition: Healthy Young and Elderly Volunteers
Interventions: Drug: Intravenous Citalopram;   Drug: Normal Saline
Outcome Measures: BOLD fMRI Response;   Genetics and Cognitive/Emotional Change
19 Unknown  Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression
Condition: Chronic Depression
Interventions: Other: CBASP psychotherapy;   Drug: Escitalopram
Outcome Measures: Depressive symptomatology after 8 weeks after randomization as measured by the MADRS;   Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization
20 Unknown  Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
Condition: Marijuana Dependence
Intervention: Drug: Escitalopram
Outcome Measures: Clean urine THC samples;   Questionnaire ratings of anxiety and depression and withdrawal symptoms